Abstract
Preeclampsia (PE) is characterized by new onset hypertension during pregnancy and is associated with oxidative stress, placental ischemia, and autoantibodies to the angiotensin II type I receptor (AT1-AA). Mitochondrial (mt) dysfunction in PE and various sources of oxidative stress, such as monocytes, neutrophils, and CD4 + T cells, have been identified as important players in the pathophysiology of PE. We have established the significance of AT1-AA, TNF-α, and CD4 + T cells in causing mitochondrial (mt) dysfunction in renal and placental tissues in pregnant rats. Although the role of mt dysfunction from freshly isolated intact placental mitochondria has been compared in human PE and normally pregnant (NP) controls, variations among preterm PE or term PE have not been compared and mechanisms contributing to mt ROS during PE are unclear. Therefore, we hypothesized PE placentas would exhibit impaired placental mt function, which would be worse in preterm PE patients than in those of later gestational ages. Immediately after delivery, PE and NP patient’s placentas were collected, mt were isolated and mt respiration and ROS were measured. PE patients at either < or >34 weeks gestational age (GA) exhibited elevated blood pressure and decreased placental mt respiration rates (state 3 and maximal). Patients delivering at >34 weeks exhibited decreased Complex IV activity and expression. Placental mtROS was significantly reduced in both PE groups, compared to NP placental mitochondria. Collectively, the study demonstrates that PE mt dysfunction occurs in the placenta, with mtROS being lower than that seen in NP controls. These data indicate why antioxidants, as a potential target or new therapeutic agent, may not be ideal in treating the oxidative stress associated with PE.
Highlights
Preeclampsia (PE) is defined by the development of new-onset hypertension with organ dysfunction with or without proteinuria after 20 weeks of gestation and affects approximately 10% of pregnancies worldwide [1,2,3,4]
We have previously shown the relevance of impaired mt function in causing hypertension in response to placental ischemia in a RUPP rat model of PE [20] and have established a link of impaired placental mt dysfunction to endothelial mt dysfunction caused by circulating AT1-AA of women with PE [21], indicating the important role that impaired mt function plays during preeclampsia
Our objective was to determine if freshly isolated placental mt from PE patients would exhibit impaired mt function based on differences in their gestational age (PE < 34 weeks compared to PE >34 samples), compared to normally pregnant (NP) controls
Summary
Preeclampsia (PE) is defined by the development of new-onset hypertension with organ dysfunction with or without proteinuria after 20 weeks of gestation and affects approximately 10% of pregnancies worldwide [1,2,3,4]. During OXPHOS, the oxidation of reducing equivalents (NADH and FADH2) at complex I (NADH dehydrogenase) and II (succinate dehydrogenase) release a pair of electrons, which, in turn travel through ETC complexes by a series of redox reactions carried out by electron carriers located within the ETC. This electron transfer causes proton translocation from matrix into the inner membrane space leading to the development of proton motive force (PMF) which in turn drives Complex V to phosphorylate ADP to form ATP. Minimal ROS production is shown to have a physiological significance, excessive amounts of ROS generation (occurs often due to mitochondrial dysfunction) leads to cell death [10,11]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.